Onxeo SA (Germany) Performance
| C4X Stock | EUR 0.08 0.02 39.32% |
On a scale of 0 to 100, Onxeo SA holds a performance score of 3. The company holds a Beta of 0.23, which implies not very significant fluctuations relative to the market. As returns on the market increase, Onxeo SA's returns are expected to increase less than the market. However, during the bear market, the loss of holding Onxeo SA is expected to be smaller as well. Please check Onxeo SA's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to make a quick decision on whether Onxeo SA's historical price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Onxeo SA are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Onxeo SA reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 14.5 M | |
| Total Cashflows From Investing Activities | -66 K |
Onxeo |
Onxeo SA Relative Risk vs. Return Landscape
If you would invest 6.40 in Onxeo SA on December 15, 2024 and sell it today you would lose (0.50) from holding Onxeo SA or give up 7.81% of portfolio value over 90 days. Onxeo SA is currently producing 0.6151% returns and takes up 12.719% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Onxeo, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Onxeo SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Onxeo SA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Onxeo SA, and traders can use it to determine the average amount a Onxeo SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0484
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | C4X | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Onxeo SA is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Onxeo SA by adding it to a well-diversified portfolio.
Onxeo SA Fundamentals Growth
Onxeo Stock prices reflect investors' perceptions of the future prospects and financial health of Onxeo SA, and Onxeo SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Onxeo Stock performance.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X | |||
| Revenue | 4.06 M | |||
| EBITDA | (4.49 M) | |||
| Cash And Equivalents | 24.46 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 9.91 M | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (8.57 M) | |||
| Earnings Per Share | (0.11) X | |||
| Total Asset | 53.06 M | |||
About Onxeo SA Performance
By analyzing Onxeo SA's fundamental ratios, stakeholders can gain valuable insights into Onxeo SA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Onxeo SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Onxeo SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people.Things to note about Onxeo SA performance evaluation
Checking the ongoing alerts about Onxeo SA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Onxeo SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Onxeo SA is way too risky over 90 days horizon | |
| Onxeo SA has some characteristics of a very speculative penny stock | |
| Onxeo SA appears to be risky and price may revert if volatility continues | |
| Onxeo SA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.06 M. Net Loss for the year was (5.94 M) with profit before overhead, payroll, taxes, and interest of 3.69 M. | |
| Onxeo SA has accumulated about 24.46 M in cash with (8.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company shares are held by company insiders |
- Analyzing Onxeo SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Onxeo SA's stock is overvalued or undervalued compared to its peers.
- Examining Onxeo SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Onxeo SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Onxeo SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Onxeo SA's stock. These opinions can provide insight into Onxeo SA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |